3.4. Safety Outcome Assessment
dermatitis, rashes, abdominal pain
DERMATITIS
All safety parameters, including blood pressure, liver function tests, and renal function tests, were within normal ranges from the baseline until the end of the study, with no significant differences found between the DW2010 and placebo groups. To identify potential AEs, the clinical condition of each individual was evaluated at predetermined intervals. During the clinical trial period, no major AEs were reported. There were no noticeable differences in specific parameters between the DW2010 and placebo groups. All major parameters were measured as part of the safety evaluation. Mild AEs occurred in seven cases in the DW2010 group and in four cases in the placebo group. Mild AEs included dermatitis contact, rashes, and abdominal pain in the DW2010 group. However, there was no direct association between these mild AEs and DW2010 ingestion (